e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Do we need to screen for latent TB when initiating a methotrexate treatment?
V. Sadovici, L. Mazur-Nicorici, V. Salaru, T. Rotaru, S. Vetrila, M. Cebanu, M. Mazur (Chisinau, Republic Of Moldova)
Source:
Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Session:
Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Session type:
Thematic Poster Session
Number:
2839
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Sadovici, L. Mazur-Nicorici, V. Salaru, T. Rotaru, S. Vetrila, M. Cebanu, M. Mazur (Chisinau, Republic Of Moldova). Do we need to screen for latent TB when initiating a methotrexate treatment?. Eur Respir J 2013; 42: Suppl. 57, 2839
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Relationship of respiratory disorders of sleep with cognitive impairment and neurological diseases
Chest X-ray and CT
Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation
Related content which might interest you:
Tuberculosis and intravenous drug users, impact of proximity measures in screening and treatment
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Latent TB infection: Patient choices and completion of treatment
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016
Is there a need for prolonged follow up in mono-drug resistant TB?
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified?
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
Prevention of latent TB reactivation in rheumatology patients prior to anti-TNF therapy: Evaluation of a risk stratification strategy in a low prevalence area
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Impact of social support programme on MDR-TB patients' treatment outcomes
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Recurrent TB in Ireland is predominantly due to relapsed infection and is frequently associated with poor compliance with therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
The effectiveness of programmatic management of latent tuberculosis infection in the Netherlands
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015
The European union standards for tuberculosis care: Do they need an update?
Source: International Congress 2014 – Tuberculosis: public health and primary prevention
Year: 2014
Preventive treatment for latent tuberculosis infection
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Is it necessary to give tuberculosis treatment daily throughout?
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Knowledge and attitude about tuberculosis disease in a health workers population
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
Cohort analysis of a large community-based latent tuberculosis screening and treatment programme in a high incidence setting in East London
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept